MicroRNA-30c-5p modulates neuropathic pain in rodents

Area of Science:

• Neuroscience
• Molecular Biology
• Pain Research

Background:

• Neuropathic pain is a chronic condition often resistant to standard treatments.
• Altered microRNA (miRNA) expression in neural pathways is linked to neuropathic pain in animal models.
• Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) knockout mice exhibit reduced pain sensitivity.

Purpose of the Study:

• To identify novel microRNAs (miRNAs) for diagnosing, treating, or predicting neuropathic pain.
• To investigate the role of miR-30c-5p in neuropathic pain.
• To explore the therapeutic potential of targeting miR-30c-5p.

Main Methods:

• Sciatic nerve injury model in rats to study miRNA expression.
• Administration of a miR-30c-5p inhibitor into the cisterna magna.
• Analysis of miR-30c-5p levels in plasma and cerebrospinal fluid (CSF) of patients with neuropathic pain due to leg ischemia.
• Logistic regression analysis for predicting pain occurrence.

Main Results:

• miR-30c-5p was upregulated in the spinal cord, dorsal root ganglia, CSF, and plasma after sciatic nerve injury in rats.
• miR-30c-5p expression positively correlated with allodynia severity.
• Inhibiting miR-30c-5p delayed pain onset and reversed established allodynia in rodents via TGF-β and the opioid system.
• Increased miR-30c-5p levels were observed in plasma and CSF of patients with neuropathic pain from leg ischemia.

Conclusions:

• miR-30c-5p is a potential biomarker for neuropathic pain.
• Targeting miR-30c-5p offers a promising therapeutic strategy for neuropathic pain.
• miR-30c-5p, combined with clinical factors, may aid in predicting neuropathic pain in patients with chronic peripheral ischemia.